Latest news and press releases about Incannex Healthcare Limited (IXHL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA).
Price
| Price | $3.59 |
| Market Cap | $43M |
| Exchange | NASDAQ |
| Country | AU |
Related companies: AGEN · CGTX · IRD · LUCD · SCLX · SEER · STSS
Explore sector: Healthcare · Biotechnology
More sections of IXHL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks